Crossmark

Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment

Crossref DOI link: https://doi.org/10.1186/s12876-022-02225-w

Published Online: 2022-03-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hyun, Hye Kyung

Zhang, Hyun-Soo

Yu, Jongwook

Kang, Eun Ae

Park, Jihye

Park, Soo Jung

Park, Jae Jun

Kim, Tae Il

Kim, Won Ho

Cheon, Jae Hee
License Information

Text and Data Mining valid from 2022-03-27

Version of Record valid from 2022-03-27
More Information

Article History

Received: 15 July 2021

Accepted: 15 March 2022

First Online: 27 March 2022

Declarations

:

: The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of Severance Hospital (IRB No. 4-2021-0213). The IRB of the Yonsei University Health System, Severance Hospital granted a waiver of informed consent because it was the retrospective study design posed minimal risks to patients.

: Not applicable.

: The authors declare that they have no competing interest.

Document is current

Any future updates will be listed below